Child-centred harm reduction.

Adolescent Child centred harm reduction Child protection Child rights Drug use Parental drug use Pregnancy Prevention

Journal

The International journal on drug policy
ISSN: 1873-4758
Titre abrégé: Int J Drug Policy
Pays: Netherlands
ID NLM: 9014759

Informations de publication

Date de publication:
11 2022
Historique:
received: 22 06 2022
revised: 05 09 2022
accepted: 08 09 2022
pubmed: 30 9 2022
medline: 26 10 2022
entrez: 29 9 2022
Statut: ppublish

Résumé

Harm reduction has become increasingly influential in drug policy and practice, but has developed primarily around adult drug use. Theoretical, practical, ethical and legal issues pertaining to children and adolescents under the age of majority - both relating to their own use and the effects of drug use among parents or within the family - are less clear. This commentary proposes a sub-field of drug policy at the intersection of harm reduction and childhood which we refer to as 'child-centred harm reduction'. We provide a definition and conceptual model, as well as illustrative questions that emerge through a child-centred harm reduction lens. Many people in different countries are already working on these kinds of issues, whose work needs greater recognition, analysis and support. In beginning to name and define this sub-field we hope to improve this situation, and inspire further international debate, collaboration, and innovation.

Identifiants

pubmed: 36174409
pii: S0955-3959(22)00273-0
doi: 10.1016/j.drugpo.2022.103857
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

103857

Informations de copyright

Copyright © 2022. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declarations of Interest The authors declare no competing interests.

Auteurs

Damon Barrett (D)

School of Public Health and Community Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden. Electronic address: damon.barrett@gu.se.

Claudia Stoicescu (C)

Monash University, Australia.

Meaghan Thumath (M)

University of British Columbia, Canada.

Emma Maynard (E)

King's College London, United Kingdom.

Russell Turner (R)

Department of Social Work, University of Gothenburg, Sweden.

Sam Shirley-Beavan (S)

Harm Reduction International, United Kingdom.

Eliza Kurcevič (E)

Eurasian Harm Reduction Association, Lithuania.

Frida Petersson (F)

Department of Social Work, University of Gothenburg, Sweden.

Jennifer Hasselgård-Rowe (J)

University of Geneva, Switzerland.

Corina Giacomello (C)

Autonomous University of Chiapas, Mexico.

Ella Wåhlin (E)

Hilary Rodham Clinton School of Law, Swansea University, United Kingdom.

Rick Lines (R)

Hilary Rodham Clinton School of Law, Swansea University, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH